Peter M Hecht
CIK 1478485 · Chief Executive Officer · last filed 2026-07-20
Peter M Hecht is a Chief Executive Officer who has filed 47 SEC Form 4 insider transactions across 2 companies since 2010. The most recent filing, for CYCN, was dated Jul 20, 2026. Across all open-market trades the lifetime net is −$4.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.4M across reported positions. 34 SEC filings were submitted jointly with IRONWOOD PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IRWD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
301 BINNEY STREET
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Cyclerion Therapeutics, Inc. (CYCN) Delisted | Chief Executive Officer | 130,037 | $23.52 | $3.06M | $5.13M | 14 | 2026-07-20 |
| IRWD | Chief Executive Officer | 2,222,216 | $4.67 | $10.37M | -$9.51M | 33 | 2019-04-03 |
Recent Filings
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-20 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Conv (C) | +351,037 | $0 | EDGAR |
| 2025-03-27 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Grant (A) | +181,818 | $500.0K | EDGAR |
| 2024-01-26 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2023-12-04 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Grant (A) | +35,000 | $0 | EDGAR |
| 2023-05-22 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Grant (A) | +225,000 | $1.95M | EDGAR |
| 2022-01-24 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-07 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Buy (P) | +823,170 | $2.70M | EDGAR |
| 2021-05-10 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Buy (P) | +302,000 | $733.9K | EDGAR |
| 2021-05-06 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Buy (P) | +698,001 | $1.69M | EDGAR |
| 2020-04-02 | Cyclerion Therapeutics, Inc. (CYCN) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.